Have to agree in principle. If CELG bought rest of majority interest now, they'd have to report our losses in financial reporting, impacting their PE. If Panzem successful, they get us cheap; very little the smaller shareholders can do about it. Of course the directors all have options and cheap shares and execs will get nice jobs with CELG so they'll recommend whatever deal CELG brings--maybe $7.50 cash or CELG stock and that will look good compared with now but actually crumbs compared to what fda approval would bring in terms of sales/profit.I guess the answer to that is, well, then buy CELG.
Thanks, I didn't know that. That makes it even more likely they would buy it. Why split the profits when they can keep the whole thing. The only reason why I can think of that they haven't bought them yet is the don't have FDA approval yet and they are waiting to get close to that point. They would have good reason to keep the price down. Lower acquisition price.